ANTI FUNGALS FINAL DECK

Question 1

Pfaller, 2012?

Answer 1

Antifungal resistance, mechanisms caused by, elevated MIC, poor clinical trial, breakthrough infections, immunocompromised

Question 2

Gupta, 2000?

Answer 2

Fusarium species, air, soil, ingestion, mycotoxosis, affects immunocompromised, potential, lesions, nondules

Question 3

Brown, 2003?

Answer 3

Azole, antifungals, inhibiting, cytochrome P450 dependent enzyme lanosterol 4 alpha demethylase, lanosterol to ergosterol, in cell membrane, cell death

Also:

Enchinocandins, fungal secondary metabolites, antifunga activity,

Target protein complex, synthesis of cell wall, enzyme 1,3 - B glucan synthase,

Still obscure

Question 4

Lupetti, 2002?

Answer 4

Resistance in fusarium, drug efflux, altered sterol synthesis, decreased azalea affinity

Question 5

Becher, 2010?

Answer 5

Proven fusarium grami nearum, azole + multidrug resistant

Question 6

Hoga, 2004?

Answer 6

Candida albicans, opportunistic pathogen, member, human microflora

Question 7

Calderone, 2001?

Answer 7

Candidiasis, skin, GI tract, vagina, infection

Host recognition biomolecules (adhesins), transition, yeast, filamentous, so adaptable

Question 8

Niimi, 2016?

Answer 8

Found that, enchinocandins, poor substrates for, multi drug efflux, in c.albicans and s. cerevisiae, did’t form resistance

Strength

Question 9

Douglas, 2001?

Answer 9

Clinically relevant if courses resistance, not strong enough